Journal ArticleJTO Clin Res Rep · September 2023
INTRODUCTION: SCLC is an aggressive malignancy with poor outcome. Most patients have disease recurrence despite treatments with multiple modalities. Subtyping of SCLC has been proposed recently, and novel agents targeting specific subtypes are actively bei ...
Full textLink to itemCite